Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Health coaches may bridge genetic testing gap for black men with prostate cancer

NCT ID NCT04763980

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why African American men with prostate cancer often miss out on genetic testing. Researchers are testing whether a community-based health coach can provide clear, culturally relevant education to help these men make informed decisions about testing. The goal is to learn how to improve access and understanding for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: CLOSED TO ENROLLMENT: INITIAL PILOT COHORT: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Have no known cancer risk genetic mutation. 4. Self-identify as Black or African American. 5. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines. ENROLLING: PART 1: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to verbally consent. 5. Self-identifies as Black or African-American. 6. Self-reports a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer. Note: Participants may or may not have had germline testing in the past, as a range of experiences is valuable for holistic feedback. Providers: 1. Self-identifies as a medical oncologist or genetics provider. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to verbally consent. ENROLLING: PART 2: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to provide written informed consent. 5. Have no known cancer risk genetic mutation. 6. Self-identify as Black or African American. 7. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per NCCN guidelines. 8. For patients recruited from the clinic: Presence of an oncology appointment within 3 months where germline testing will be discussed. Exclusion Criteria: CLOSED TO ENROLLMENT: INITIAL PILOT COHORT. 1. Prior germline genetic test. 2. Age \<18 years old. 3. Unable to read or answer forms. ENROLLING: PART 1: 1\. Contraindication to any study-related procedure or assessment. ENROLLING: PART 2: 1. Self-reports prior germline genetic test. 2. Contraindication to any study-related procedure or assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • San Francisco Veterans Administration Medical Center

    NOT_YET_RECRUITING

    San Francisco, California, 94121, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Zuckerberg San Francisco General Hospital

    RECRUITING

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.